Sun Pharma Advanced Research Company Limited SPARC NSEPHARMA
Company Overview
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Why Investors Should Care
Generates a return on equity of 116.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 111.8%.
Net profit has compounded at 265.9% per year over the last five years.
Trades at a P/E of 4.2, below the sector median of 41.6.
Recent Developments
- Mar 2026 Revenue of ₹39.15 Cr (-45.5% YoY); net profit ₹1,553.20 Cr.
- Trailing 12 Months Year-on-year growth — revenue -45.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -45.3%, profit CAGR 265.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -45.27% |
| 1 Year: | -45.45% |
Compounded Profit Growth
| 5 Years: | 265.94% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +40.57% |
| 6 Months: | +60.91% |
| 3 Months: | -4.65% |
| 1 Month: | -8.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)45.29 · Neutral
P/E of 4.17 is below the sector median of 41.64 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 116.0%.
- Healthy ROCE of 111.8%.
- Profit CAGR of 265.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -45.3% CAGR over 5 years.
- Trading 28.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPARC Sun Pharma Advanced Research Company Limited NSEPHARMA | 199.47 | 4.17 | ₹6,473.23 Cr | 0.00% | 111.85% | 116.01% | -45.27% | 265.94% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.00 Cr | 24.00 Cr | 21.00 Cr | 14.00 Cr | 17.00 Cr | 17.00 Cr | 13.00 Cr | - | 27.19 Cr | 9.64 Cr | 7.86 Cr | 8.45 Cr | 1,853.22 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 17.18 Cr | 10.67 Cr | 14.11 Cr | 13.48 Cr | 8.00 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 10.01 Cr | -1.03 Cr | -6.25 Cr | -5.03 Cr | 1,845.22 Cr |
| Operating Expenses | 137.00 Cr | 126.00 Cr | 113.00 Cr | 116.00 Cr | 122.00 Cr | 110.00 Cr | 116.00 Cr | - | 66.14 Cr | 53.73 Cr | 62.03 Cr | 54.18 Cr | 74.42 Cr |
| Operating Income | -93.00 Cr | -105.00 Cr | -94.00 Cr | -106.00 Cr | -109.00 Cr | -96.00 Cr | -106.00 Cr | - | -56.13 Cr | -54.76 Cr | -68.28 Cr | -59.21 Cr | 1,770.80 Cr |
| EBITDA | -90.00 Cr | -102.00 Cr | -91.00 Cr | -103.00 Cr | -106.00 Cr | -93.00 Cr | -103.00 Cr | - | -53.18 Cr | -42.94 Cr | -65.71 Cr | -69.00 Cr | 1,775.00 Cr |
| Interest Expense | 0 | 0 | 0 | 0 | 1.00 Cr | 1.00 Cr | 1.00 Cr | - | 4.54 Cr | 6.19 Cr | 7.52 Cr | 8.78 Cr | 11.64 Cr |
| Pretax Income | -82.00 Cr | -95.00 Cr | -86.00 Cr | -100.00 Cr | -105.00 Cr | -96.00 Cr | -107.00 Cr | - | -60.67 Cr | -51.81 Cr | -75.79 Cr | -80.35 Cr | 1,760.96 Cr |
| Tax Provision | -0 | -0 | -0 | -0 | -0 | -0 | -0 | - | -90.00 L | 6.00 L | 6.00 L | 7.00 L | -38.00 L |
| Net Income | -82.00 Cr | -95.00 Cr | -86.00 Cr | -100.00 Cr | -106.00 Cr | -96.00 Cr | -107.00 Cr | - | -59.77 Cr | -51.87 Cr | -75.85 Cr | -80.42 Cr | 1,761.34 Cr |
| Diluted EPS | -2.53 | -2.94 | -2.66 | -3.07 | -3.26 | -2.96 | -3.31 | - | -1.84 | -1.60 | -2.34 | -2.48 | 54.27 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 238.78 Cr | 75.55 Cr | 71.77 Cr | 39.15 Cr |
| Cost of Revenue | - | 176.74 Cr | 135.79 Cr | 109.96 Cr | 51.39 Cr |
| Gross Profit | - | 62.04 Cr | -60.24 Cr | -38.19 Cr | -12.24 Cr |
| Operating Expenses | - | 285.69 Cr | 351.26 Cr | 295.87 Cr | -1,611.17 Cr |
| Operating Income | - | -223.64 Cr | -411.50 Cr | -334.06 Cr | 1,598.93 Cr |
| EBITDA | - | -203.18 Cr | -373.13 Cr | -321.85 Cr | 1,594.81 Cr |
| Interest Expense | - | 7.63 Cr | 1.19 Cr | 8.54 Cr | 31.59 Cr |
| Pretax Income | - | -222.58 Cr | -386.83 Cr | -342.78 Cr | 1,553.01 Cr |
| Tax Provision | - | 0 | 38.20 L | -27.18 L | -19.44 L |
| Net Income | - | -222.58 Cr | -387.21 Cr | -342.51 Cr | 1,553.20 Cr |
| Diluted EPS | - | -7.82 | -11.93 | -10.55 | 47.86 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 830.13 Cr | 515.04 Cr | 335.53 Cr | 2,170.88 Cr |
| Current Assets | - | 454.96 Cr | 269.39 Cr | 26.20 Cr | 1,862.43 Cr |
| Cash & Equivalents | - | 58.36 L | 5.33 Cr | 1.96 Cr | 1.16 Cr |
| Inventory | - | - | - | - | - |
| Receivables | - | 32.71 Cr | 15.53 Cr | 16.06 Cr | 8.27 Cr |
| Total Liabilities | - | 317.35 Cr | 389.29 Cr | 552.48 Cr | 832.05 Cr |
| Current Liabilities | - | 178.95 Cr | 265.06 Cr | 374.24 Cr | 754.11 Cr |
| Long Term Debt | 0 | - | 0 | 100.00 Cr | 0 |
| Total Debt | - | 15.68 Cr | 57.66 Cr | 265.13 Cr | 557.80 Cr |
| Total Equity | - | 512.78 Cr | 125.76 Cr | -216.95 Cr | 1,338.83 Cr |
| Shares Outstanding | - | 32.45 Cr | 32.45 Cr | 32.45 Cr | 32.45 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -69.12 Cr | -429.19 Cr | -360.29 Cr | -238.78 Cr |
| Investing Cash Flow | - | -548.28 Cr | 391.53 Cr | 157.66 Cr | -23.50 Cr |
| Financing Cash Flow | - | 616.76 Cr | 42.41 Cr | 199.26 Cr | 261.39 Cr |
| Capital Expenditure | - | -15.39 Cr | -26.51 Cr | -10.34 Cr | -23.83 Cr |
| Free Cash Flow | - | -84.50 Cr | -455.70 Cr | -370.63 Cr | -262.61 Cr |
| Net Change in Cash | - | -64.06 L | 4.74 Cr | -3.38 Cr | -88.73 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 26.0% | -79.7% | -53.2% | -31.3% |
| Operating Margin % | - | -93.7% | -544.7% | -465.5% | 4,084.3% |
| Net Margin % | - | -93.2% | -512.6% | -477.3% | 3,967.5% |
| ROE % | - | -43.4% | -307.9% | 157.9% | 116.0% |
| ROCE % | - | -34.3% | -164.6% | 863.1% | 112.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SPARC
Sun Pharma Advanced Research Company Stock Price Forecast. Should You Buy SPARC.NS? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTFA2UmFqRUEwdmNfT242X1hQaWVKRTJ2OFRzYTUxUVFfbTItX09vM2ZvbEtjYjQzZFRsWEczUU1MS1FiU2lZaFJ0MnNDUm9oUQ?oc=5" target="_blank">Sun Pharma Advanced Research Company Stock Price Forecast. Sh…
Total debt per share of Sparc Technologies Ltd – HAM:NLR - TradingView
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPUEx1M0V5T3pmU2VSUkNmXzF2THlPakdpRm9qeE0xdTNYTWNlelljMXBBZDJCaUNKOXdtNUt6ckRLOElWR3c1M3pYNnZ4R1BWYjgyRjNaenRUc2NTNHZTaUFGemxSYUx4YTQ5OWRqQWgyOXdLOGM5TUJ5Z3hqU2RWZ1ExMkhQTlJkeVNKM1…
Concerns Surrounding Sun Pharma Advanced Research's (NSE:SPARC) Performance - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxPY0xhRDgwdE1sNV9JZ25NZE5lMGdaZUVSNHVuZlVQMlNJLVVjVmUxeWpNTDFBV0o4N05IZFI0dF93S1hYSnFpRTdYaGRYNWdBbFZtR3UwOUN2RTBwYWcwVWFoUEVSSVpmX1dEeERjdDlBTUNyY2dmZFZDZHdEZ2dSU1ZJbzZiSDUyUFh2dH…
SPARC Share Price: Buy, Hold or Sell Guide - Univest
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOU3Q1S3FBM21oQloyc25yYVJjOWdTdktnYTl3VEJZQ2ZvN3VCLTktQTE5Wm83THVsMHVWYjgwR0ZnUEV3WWxKTDQ0dU1mT3E5Yk5QSzB3YTI3UmdaTEFXc1NvRDRZT1JZMkJUN0RnVXVnV0pKWHFQNXdoVXFqd2dja2JEN0J4NXAtOV90ZF…
SPARC AI Issues First Equity Awards in Over Three Years After Shareholder Approval - finance.biggo.com
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE9tVE9GSXh0OWpWcVA5UlN5Wk1TamVWeDg5Tkx1WUVJNTRHR1RCYXJ4UGEwdW1MQ0FXU2dUMGZBMVlDc05WWmIxVHYtbk1UMF9waE1kbzd5dUNSZFkxZWNEVlkyaWNLUzhmYmEyVi1vWndNTGhmalE?oc=5" target="_blank">SPARC AI…
SPARC AI Stock Falls 3.38% as Wider Losses, Valuation Risk and Volatility Pressure Investor Sentiment - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxPbmwxWjdYUkxQaDBaVU5EOW16VFU2alFYelRib0pkMHI4MVR0Rmt1MFpLNVdxeTVNMkNYRUFTMXhqcWF4MDNZVnJOQTI4Y3JSVWlqZVdTSGZmSTV5V09Tdk0ySUVHQVNfbU5NUU56alV4WkZkXzJTQ3VvTkRXLWl4a3dkTG92VGkxd1pJVT…
SPARC — Frequently Asked Questions
What is the current share price of Sun Pharma Advanced Research Company Limited (SPARC)?
As of 2026-09-08 04:53 IST, Sun Pharma Advanced Research Company Limited (SPARC) trades at ₹199.47 on NSE. Its 52-week range is ₹108.71 to ₹277.57.
What is the market capitalisation of SPARC?
Sun Pharma Advanced Research Company Limited (SPARC) has a market capitalisation of ₹6,473.23 Cr on NSE.
What is the P/E ratio of SPARC?
SPARC trades at a trailing price-to-earnings (P/E) ratio of 4.17. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 5.17.
What is the return on equity (ROE) of SPARC?
SPARC has a return on equity (ROE) of 116.01%. Its return on capital employed (ROCE) is 111.85%.
Is SPARC a good stock to buy?
This page provides a data-driven analysis of Sun Pharma Advanced Research Company Limited (SPARC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.